Literature DB >> 3595811

Cytogenetic studies in 69 patients with myelodysplastic syndromes (MDS).

H J Weh, A Calavrezos, D Seeger, R Kuse, D K Hossfeld.   

Abstract

Cytogenetic studies were performed in 69 patients with myelodysplastic syndromes classified according to the FAB proposals. Overall incidence of chromosomal anomalies was 48% with 5q-, +8, 12p-,-7/7q- being the aberrations most often found. The 12p- chromosome showed a close correlation with a prior exposure to mutagenic agents and CMML. Although there were no group-specific cytogenetic anomalies, FAB classification strongly influenced their incidence. They were lower (36%) in RA/RA-S than in RAEB/RAEB-T/CMML (53%). Chromosomal anomalies were significantly more often found in patients with a prior exposure to carcinogenic agents (80%) than in unexposed patients (33%). The presence of chromosomal anomalies did not predict a higher risk of leukemic transformation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3595811     DOI: 10.1111/j.1600-0609.1987.tb01157.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  DNA index and karyotype analysis in myelodysplasia.

Authors:  T G Hoy; A D Geddes; A Jacobs
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

2.  Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance.

Authors:  M Werner; H Maschek; V Kaloutsi; H Choritz; A Georgii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 3.  Chromosome and molecular abnormalities in myelodysplastic syndromes.

Authors:  Pierre Fenaux
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

4.  Correlations between cytogenetics and morphology in myelodysplastic syndromes.

Authors:  L Vila; C Charrin; E Archimbaud; D Treille-Ritouet; J Fraisse; P Felman; D Fiere; D Germain
Journal:  Blut       Date:  1990-04

Review 5.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.